Indaptus Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Indaptus Therapeutics, Inc. (INDP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 48.43 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2024-03-13
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2023-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2023-09-30 was 34.68K shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-12-31 was 90.00K shares, a 269.75% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-09-30 was 0.00 shares.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 48.43K shares, a 60.70% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 123.24K shares, a 267.70% increase from fiscal 2021.
- Indaptus Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 33.52K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 34.68K shares derived: sum of 2 quarters · filed 2024-03-13 | 48.43K shares 10-K · filed 2024-03-13 | |
| 2023-09-30 | 34.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 48.43K shares 10-Q · filed 2023-11-06 | ||
| 2023-06-30 | 13.75K shares 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | 90.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 90.00K shares derived: sum of 2 quarters · filed 2023-03-17 | 90.00K shares derived: sum of 3 quarters · filed 2023-03-17 | 123.24K shares 10-K · filed 2023-03-17 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-10 | 33.24K shares 10-Q · filed 2022-11-10 | 57.58K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 33.24K shares 10-Q · filed 2022-08-08 | 57.58K shares derived: sum of 3 quarters · filed 2022-08-08 | |
| 2022-03-31 | 33.24K shares 10-Q · filed 2022-05-12 | 57.58K shares derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2021-12-31 | 24.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 33.52K shares 10-K · filed 2022-03-21 | ||
| 2021-09-30 | 9.18K shares 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |